MBP 3.23% 3.0¢ metabolic pharmaceuticals limited

mbp-westpac valuation - fyi

  1. 832 Posts.
    The key share price driver will be the success of phase 2B trials of AOD9604 that will form a platform to negotiate a favourable deal with an international pharmaceutical company. A deal could take up to twelve months to resolve. Progen (PGL) has been rising steadily over the past year on the expectation of a significant deal with a pharmaceutical company therefore for those speculative investors looking for a punt MBP represents an opportunity to accumulate before the hype in the stock begins to build.
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.